09.10.24 -- Bridge RNAs: Principles, Applications, And Challenges

Explore how bioavailability of poorly soluble APIs can be improved and patient compliance enhanced by reducing the size or number of tablets that a patient must take to achieve the required dose.

Industry expert Dr. Loretta Itri sits down to explore the promise of TRODELVY®️ and other antibody-drug conjugates as transformative treatments for a range of malignancies and intractable diseases.

Understand the challenges faced by a large CDMO as well as the solutions that were provided to achieve time savings, cost savings, and the removal of a major downstream process limitation.

Explore an integrated service package designed to simplify and accelerate the development pathway, even for APIs with challenging properties such as low aqueous solubility and poor bioavailability.

Review the design of dissolution media to support biopredictive dissolution testing and a method for selecting practical, physiologically relevant media based on drug, formulation, and GI fluid properties.

A healthcare manufacturer facing space constraints and regulatory pressures outsourced their stability storage needs to another company, resulting in reduced costs and focus on core competencies.